Prostate cancer

Prostate cancer is a malignancy arising in the prostate, a gland situated below the bladder and surrounding part of the urethra. Most cases are adenocarcinomas, originating in glandular cells. Its course varies considerably: some tumors remain localized and grow slowly, whereas others invade neighboring tissues or spread to distant organs, particularly bones. This variation makes distinguishing clinically significant disease from tumors unlikely to cause harm central to its diagnosis and management. (cancer.gov)

Prostate cancer is a major global public health concern. The International Agency for Research on Cancer estimated that more than 1.5 million cases occurred worldwide in 2024, making it the second most commonly occurring cancer in men. Age, family history, and inherited genetic variants influence risk, while access to detection and treatment contributes to differences in outcomes between populations. (iarc.who.int)

Detection commonly involves prostate-specific antigen testing, imaging, and tissue biopsy, with tumor grade and stage establishing the disease’s characteristics. Management encompasses active surveillance, surgery, radiation therapy, hormonal treatment, and systemic therapies for advanced disease. The subject also includes screening benefits and harms, hereditary susceptibility, treatment-related changes in quality of life, and the development of molecularly targeted approaches. (cancer.org)

Prostate anatomy and the origins of disease

The prostate is a gland of the male reproductive system situated immediately below the urinary bladder and in front of the rectum. It surrounds the proximal urethra, the passage through which urine leaves the bladder; this segment is called the prostatic urethra. Its posterior surface lies close enough to the rectum to be palpated through the rectal wall during a digital rectal examination. The seminal vesicles are separate glands behind the bladder and above the posterior prostate, with their ejaculatory ducts passing through the prostate to open into the urethra. Prostatic secretions contribute to semen, the fluid that carries sperm, while muscular contractions in the gland help propel semen into the urethra during ejaculation. The prostate therefore participates in reproduction but also occupies a position where enlargement can interfere with urinary flow. (cancer.gov)

The glandular prostate is divided into three principal anatomical zones rather than a uniform mass of tissue. The peripheral zone occupies much of the posterior and lateral gland and lies next to the rectum. The transition zone surrounds the prostatic urethra and, before age-related enlargement, accounts for approximately 5% of glandular tissue. The central zone is cone-shaped, with its broad end at the prostate’s base, and surrounds the ejaculatory ducts. In addition, the anterior fibromuscular stroma consists predominantly of muscle and connective tissue rather than secretory glands. These divisions describe tissue compartments with different relationships to the urethra and ejaculatory ducts; they are not stages of disease. (training.seer.cancer.gov)

Most prostatic adenocarcinomas originate in the peripheral zone, whereas benign prostatic hyperplasia (BPH) characteristically develops in the transition-zone and periurethral region. Cancer can nevertheless arise in any glandular zone, including tissue affected by benign enlargement. A concrete demonstration of this distribution came from John E. McNeal and colleagues’ December 1988 study of 104 prostates removed by radical prostatectomy. Among the 88 cancers for which a probable zone of origin could be assigned, 68% originated in the peripheral zone, 24% in the transition zone, and 8% in the central zone. These figures describe that surgical series rather than fixed proportions for every population. Their anatomical distinction also explains why tissue removed through the urethra for obstruction preferentially samples transition-zone disease rather than the peripheral region where most cancers originate. (pubmed.ncbi.nlm.nih.gov)

A primary prostate malignancy is a cancer that originates in the prostate, not simply any malignant growth found within or next to it. The predominant form is adenocarcinoma arising from glandular cells; rarer histological types are distinguished separately. BPH is nonmalignant tissue growth and is not synonymous with cancer, while prostatitis denotes inflammation of the prostate and may be bacterial or nonbacterial. Enlargement, inflammation, and malignancy can produce overlapping findings, including urinary difficulties or increased blood concentrations of prostate-specific antigen. Neither gland size nor that laboratory finding alone establishes the presence or origin of a malignant tumor. (cancer.gov)

The distinction between a primary tumor and secondary involvement remains important because the prostate borders other pelvic organs. For example, a bladder cancer may grow directly into the prostate; it remains a bladder primary with local extension rather than becoming a primary prostate cancer. Conversely, a cancer originating in the prostate may extend into the bladder, seminal vesicles, or rectum without changing its site of origin. Anatomical location must therefore be interpreted together with tissue pathology and the demonstrated origin of the tumor, rather than treating the organ containing malignant cells as sufficient evidence of the primary site. (cancer.gov)

Epidemiology and population burden

The International Agency for Research on Cancer (IARC) estimated 1,467,854 new prostate cancer cases and 397,430 deaths worldwide in 2022 in GLOBOCAN 2022, whose geographic coverage comprised 185 countries and territories. The corresponding world-age-standardized incidence and mortality rates were 29.4 and 7.3 per 100,000 males annually. These are estimates rather than a complete enumeration of diagnoses and deaths: national inputs differ in timeliness, representativeness, and quality, and some estimates require projections or modelling where direct observations are incomplete. The GLOBOCAN methodology includes uncertainty intervals to reflect these sources of error beyond random variation; the precision of the published case totals should therefore not be mistaken for equally precise knowledge in every country. (gco.iarc.who.int)

Geographic burden differs depending on whether it is measured as absolute numbers or age-standardized rates. In 2022, Europe accounted for 473,011 diagnoses, or 32.2% of the worldwide total, and Asia for 386,424, or 26.3%. Asia nevertheless had substantially lower incidence rates than many European populations because its large population contributes many cases even when individual age-specific rates are relatively low. Age standardization applies a common reference age distribution, allowing comparisons that are less affected by differences in population age structure. An analysis of GLOBOCAN 2022 found incidence rates ranging from 82.8 per 100,000 males in Northern Europe to 6.4 in South-Central Asia. Mortality followed a different geography: Southern Africa had the highest regional age-standardized mortality rate, 29.7 per 100,000, compared with 3.1 in South-Central Asia. High recorded incidence therefore does not necessarily identify the populations with the highest fatal disease burden. (gco.iarc.who.int)

Occurrence is strongly concentrated in older age groups. In United States SEER registry data for 2019–2023, the median age at diagnosis was 68 years, and 43.3% of diagnoses occurred at ages 65–74; only 0.3% occurred at ages 35–44. The median age at death in national mortality data for 2020–2024 was 79 years. Because incidence increases with age, population aging can increase the number of diagnoses without a corresponding increase in age-standardized incidence. Counts, crude rates, and standardized rates consequently answer different questions: counts describe the volume of disease requiring services, whereas standardized rates facilitate comparisons between populations or periods with different age structures. (seer.cancer.gov)

Recorded incidence also depends on how intensively disease is sought. Testing for prostate-specific antigen (PSA), followed by diagnostic assessment and biopsy, detects cancers that otherwise might remain undiagnosed, including indolent tumors that would never cause symptoms during the affected person’s lifetime. In a 2024 study led by IARC epidemiologist Salvatore Vaccarella, incidence trends in 26 European countries during 1980–2017 varied alongside patterns of PSA testing. Across the study period, incidence varied approximately twentyfold between countries, compared with a fivefold variation in mortality, supporting a substantial contribution from overdiagnosis. Registry completeness and access to diagnostic services also affect ascertainment: limited coverage or unavailable tissue diagnosis can reduce recorded incidence, while estimates based on regional proxies may not fully represent national populations. (iarc.who.int)

Disparities within countries reflect interacting clinical, environmental, genetic, and social determinants of health, rather than racial categories functioning as uniform biological explanations. In United States mortality data for 2020–2024, age-adjusted death rates were 36.2 per 100,000 non-Hispanic Black males and 18.1 per 100,000 non-Hispanic White males. NCI also documents a disproportionate burden of aggressive disease among African American men and an association between unreliable health-care access and later-stage cancer diagnosis. A 2019 analysis by Robert Dess and colleagues included 306,100 men with nonmetastatic prostate cancer across SEER, Veterans Affairs centers, and randomized trials. Black race was not associated with worse prostate-cancer-specific mortality in settings with standardized access or treatment and follow-up. That finding concerns outcomes after nonmetastatic diagnosis; it does not establish equal susceptibility to developing cancer or equal likelihood of metastatic presentation. (seer.cancer.gov)

Risk factors and hereditary susceptibility

Increasing age and family history are established risk factors. Prostate cancer is rare before age 50, and its occurrence increases with age. Familial risk rises with the number of affected relatives and is greater when relatives were diagnosed young. A meta-analysis of 33 studies reported a relative risk of 2.48 for men with one affected first-degree relative and 4.39 for those with two or more, compared with men without the corresponding family history. These are relative risks, not probabilities of developing cancer. Familial clustering does not by itself establish a single-gene disorder: inherited susceptibility can involve numerous variants rather than one identifiable pathogenic change. (cancer.gov)

Rare pathogenic variants in BRCA2 are particularly important because they increase susceptibility and are associated with more aggressive disease; the association with BRCA1 is weaker. Both genes encode proteins involved in DNA repair. An inherited harmful variant leaves a functional second copy, but subsequent loss or alteration of that copy can impair repair in individual cells. The National Cancer Institute’s 2024 fact sheet gives estimated prostate-cancer risks by age 80 of 19%–61% for BRCA2 carriers and 7%–26% for BRCA1 carriers. These ranges illustrate incomplete penetrance: carrying a pathogenic variant raises risk but does not make cancer inevitable. Estimates depend on the variant, age, family history, and population studied. (cancer.gov)

HOXB13 encodes a transcription factor important in prostate development. In 2012, Charles M. Ewing and colleagues identified its G84E variant in four prostate-cancer families; all 18 affected men with available DNA carried it. Subsequent studies, predominantly in populations of European ancestry, support an approximately threefold to fivefold increase in overall risk, with stronger associations for early-onset disease. Its association with aggressive cancer is less clear. Pathogenic variants in MLH1, MSH2, MSH6, and PMS2, which participate in DNA mismatch repair, cause Lynch syndrome and can also increase prostate-cancer susceptibility. This syndrome explains why a family history of colorectal or endometrial cancer may be relevant alongside prostate cancer. Risk estimates are not interchangeable across these genes. (nejm.org)

Common susceptibility variants generally have much smaller individual effects than these rare variants. A 2023 multi-ancestry genome-wide association study involving 156,319 cases and 788,443 controls identified 187 additional risk variants, bringing the total in that analysis to 451. A polygenic risk score combines the effects of many risk-associated alleles, weighted by their estimated associations. It describes a distribution of inherited susceptibility rather than a yes-or-no hereditary diagnosis. The study’s score was associated with risk across ancestry groups, but effect sizes differed; unequal representation in genetic research limits the transferability and calibration of scores between populations. A score associated with cancer occurrence does not necessarily predict aggressive disease equally well. (nature.com)

Germline testing examines non-tumor DNA, usually from blood or saliva, for inherited variants that may also be present in biological relatives. Tumor testing examines cancer DNA for alterations potentially relevant to treatment; these can be acquired during tumor development or inherited. Consequently, a pathogenic variant detected in a tumor does not alone establish hereditary susceptibility, and confirmation in a non-tumor sample may be needed. Conversely, an uninformative negative germline result does not eliminate familial risk, because testing may not explain the inherited factors responsible for a family’s cancers. (cancer.gov)

Genetic counseling is the interpretive process surrounding testing, not the laboratory test itself. It assesses the pedigree, explains possible results, and addresses implications for relatives and informed consent. For the autosomal-dominant predispositions discussed here, a carrier can transmit the variant through either the maternal or paternal line, with a 50% probability for each child; inheritance of the variant is distinct from development of cancer. Once a familial pathogenic variant is identified, targeted testing can establish which relatives carry it. A variant of uncertain significance lacks sufficient evidence to classify it as harmful or benign and does not establish a hereditary cancer diagnosis. (cancer.gov)

Molecular biology and disease progression

The androgen receptor (AR) is a hormone-activated transcription factor that regulates gene expression in prostate epithelial cells and most prostate adenocarcinomas. Testosterone, produced predominantly by the testes, and dihydrotestosterone (DHT) bind AR and activate growth-related transcriptional programs. Within prostate tissue, 5α-reductase enzymes convert testosterone to DHT, which binds AR more strongly than testosterone. Activated AR acts in the nucleus to regulate specific genes. Lowering circulating androgens or blocking their interaction with AR therefore suppresses many prostate cancers, but does not necessarily eliminate every malignant cell. Adrenal androgen precursors and androgen production within tumor tissue can provide additional sources of receptor activation. (cancer.gov)

Acquired genomic alterations create several molecular routes to malignancy rather than a single obligatory sequence. In 2015, The Cancer Genome Atlas Research Network analyzed 333 primary prostate carcinomas: 74% belonged to seven molecular subtypes defined by fusions involving ERG, ETV1, ETV4, or FLI1, or by mutations in SPOP, FOXA1, or IDH1. AR-associated transcription varied substantially between these groups. Alterations affecting growth signaling and tumor suppression also occur; loss of PTEN, for example, removes a restraint on the PI3K–AKT pathway. These findings describe molecular diversity within a studied cohort, not a universal progression pathway or a classification that replaces histological grading. (pmc.ncbi.nlm.nih.gov)

Defective DNA repair provides another route to genomic instability. BRCA2 and BRCA1 participate in homologous recombination, which repairs double-strand DNA breaks using a homologous template; loss of their function can promote chromosomal rearrangements and other accumulated abnormalities. In a 2015 study led by Dan Robinson and Eliezer Van Allen, sequencing of metastatic castration-resistant tumors from 150 patients identified DNA-repair or recombination-gene alterations in 34 patients (22.7%). BRCA2 loss occurred in 19 patients, approximately 90% of whom had both gene copies affected. The findings included both acquired alterations and inherited variants, which must be distinguished when interpreting tumor sequencing. DNA mismatch repair corrects replication errors through proteins including MSH2, MSH6, MLH1, and PMS2. Its failure can produce hypermutation and unstable repetitive DNA sequences, termed microsatellite instability. Wassim Abida and colleagues reported high microsatellite instability or mismatch-repair deficiency in 32 of 1,033 evaluable patients (3.1%) in a study published online in December 2018. (pmc.ncbi.nlm.nih.gov)

Tumor heterogeneity exists both between patients and among malignant cell populations within an individual. Clonal evolution occurs as descendant populations acquire different alterations and expand under different selective pressures. Treatment can suppress sensitive populations while allowing resistant subclones to become dominant; resistance therefore need not represent a uniform change in every tumor cell. In 2015, Gunes Gundem and colleagues reconstructed relationships among 51 tumor samples from 10 patients with lethal metastatic disease. Their analysis demonstrated branching evolution, transfer of cells between metastatic sites, and seeding involving multiple subclones. The resulting pattern is more complex than a primary tumor producing genetically identical secondary deposits. (pmc.ncbi.nlm.nih.gov)

Castration resistance means progression despite very low circulating testosterone, not necessarily complete independence from androgen signaling. Persistent AR activity can result from amplification of the AR gene, receptor mutations, and continued intratumoral androgen availability. Receptor splice variants provide another mechanism: AR-V7 lacks the usual ligand-binding domain but retains transcriptional activity, allowing signaling without normal hormone binding. In a 2014 prospective study, Emmanuel Antonarakis and colleagues examined circulating tumor cells from 62 patients starting enzalutamide or abiraterone. AR-V7 detection was associated with absent PSA responses and shorter progression-free survival, although this small observational study did not establish a universally applicable treatment-selection rule. (pmc.ncbi.nlm.nih.gov)

Other resistant populations reduce their reliance on AR through changes in cellular identity, or lineage plasticity. Experimental work published by Ping Mu and colleagues in 2017 showed that combined loss of TP53 and RB1 enabled SOX2-mediated reprogramming and resistance to antiandrogen treatment in prostate cancer models. Such changes can support a shift away from an AR-dependent luminal identity toward alternative cellular programs. This mechanism is distinct from restoration of AR signaling and illustrates why resistant disease can contain biologically different populations requiring separate molecular characterization. (pubmed.ncbi.nlm.nih.gov)

Histological types and tumor grading

Conventional acinar adenocarcinoma is the predominant histological type of prostate cancer. Its malignant glandular cells infiltrate the surrounding tissue, usually without the basal-cell layer present in benign prostatic glands. Ductal adenocarcinoma typically contains tall columnar cells arranged in papillary or cribriform structures and frequently coexists with acinar carcinoma. The 2022 World Health Organization classification reserves “ductal adenocarcinoma” in prostatectomy specimens for tumors with more than 50% ductal morphology; needle biopsy specimens are described as “adenocarcinoma with ductal features.” Small-cell neuroendocrine carcinoma has scant cytoplasm, nuclear molding, frequent mitoses, and often necrosis; it can occur initially or emerge after hormonal treatment, sometimes mixed with adenocarcinoma. Focal neuroendocrine-marker expression in otherwise conventional adenocarcinoma does not by itself establish this diagnosis. Other uncommon forms include large-cell neuroendocrine carcinoma and adenoid cystic (basal cell) carcinoma. (pmc.ncbi.nlm.nih.gov)

The Gleason grading system, developed by Donald Gleason, assesses microscopic growth architecture rather than simply nuclear appearance. In contemporary practice, invasive adenocarcinoma is assigned patterns 3–5: pattern 3 consists of separate, well-formed glands; pattern 4 includes poorly formed, fused, glomeruloid, and cribriform glands; and pattern 5 shows little or no gland formation, with solid growth, cords, single cells, or comedonecrosis. Patterns 1 and 2 are no longer used in routine contemporary grading. A score combines two patterns, doubling the pattern when only one is present. Gleason grading applies principally to acinar and ductal adenocarcinoma, not to small-cell neuroendocrine or basal-cell carcinoma. (pmc.ncbi.nlm.nih.gov)

Scoring rules differ between needle biopsies and radical prostatectomy specimens because biopsies sample only a small portion of the tumor. In a biopsy containing several patterns, the most prevalent pattern is combined with the highest-grade pattern, even when the latter is limited. Thus, a core containing 60% pattern 4, 36% pattern 3, and 4% pattern 5 is scored $4+5=9$. In prostatectomy specimens, the two predominant patterns generally determine the score; under the 2019 International Society of Urological Pathology (ISUP) recommendations, a higher-grade component occupying less than 5% is reported separately as a minor or tertiary pattern. For example, predominantly pattern 3 with secondary pattern 4 and less than 5% pattern 5 remains $3+4=7$, with minor pattern 5 recorded. (pmc.ncbi.nlm.nih.gov)

The five-tier Grade Group system, endorsed at the 2014 ISUP consensus conference, maps Gleason scores as follows: Grade Group 1, $3+3=6$; Group 2, $3+4=7$; Group 3, $4+3=7$; Group 4, score 8, comprising $4+4$, $3+5$, or $5+3$; and Group 5, scores 9–10, comprising $4+5$, $5+4$, or $5+5$. Although both total 7, $3+4$ and $4+3$ are not equivalent: the former is predominantly well-formed glands, whereas the latter is predominantly pattern 4 and has less favorable outcomes. Reporting the percentage of pattern 4 further distinguishes tumors within these groups. (uroweb.org)

Intraductal carcinoma of the prostate consists of malignant cells expanding pre-existing ducts or acini while retaining at least part of their basal-cell layer; it is distinct from ductal adenocarcinoma. It commonly accompanies aggressive invasive disease and is reported explicitly. Joint GUPS–ISUP recommendations published in December 2025 state that intraductal carcinoma associated with invasive cancer should enter the Gleason score according to its architecture, unless spatially distinct from the invasive tumor; isolated intraductal carcinoma is not graded. Invasive cribriform architecture—sheets of malignant cells containing multiple luminal spaces—is pattern 4 and is also specifically reported because it carries adverse prognostic information beyond the numerical score. (pmc.ncbi.nlm.nih.gov)

Biopsy reports additionally record the number of cancer-positive cores relative to the number sampled, their anatomical sites, and the extent of involvement, expressed as cancer length in millimeters or percentage of each core. These measurements describe sampled tumor burden, not the percentage of the entire prostate occupied by cancer. Site-specific grades preserve information about heterogeneity that a single overall score can obscure. Together, grade, pattern-4 proportion, cribriform or intraductal findings, and core involvement contribute to subsequent prognostic classification. (documents.cap.org)

Clinical presentation and patterns of spread

Localized prostate cancer frequently causes no symptoms. A tumor confined to the gland may therefore be discovered during investigation of an abnormal prostate-specific antigen (PSA) result rather than because of discomfort or altered urination. Absence of symptoms does not establish that a tumor is biologically indolent, and symptoms alone cannot determine whether cancer is present or how far it has spread. Even metastatic disease can be asymptomatic, depending on the size and location of secondary deposits. (cancer.gov)

When urinary symptoms occur, they may include difficulty initiating urination, a weak or interrupted stream, incomplete bladder emptying, and increased frequency, particularly at night. These findings are nonspecific: benign prostatic hyperplasia is a much more common explanation for difficulty urinating, while prostatitis can produce urinary discomfort and similar changes in bladder habits. Hematuria—blood in the urine—and blood in semen may also occur, but neither finding identifies prostate cancer by itself. Benign enlargement, inflammation, and cancer can coexist, so urinary complaints cannot reliably distinguish among them. (cancer.gov)

Local progression involves extension beyond the prostate into surrounding tissues, including the seminal vesicles; more extensive disease can invade the bladder, rectum, or pelvic wall. Growth affecting the urethra or bladder outlet may cause increasing obstruction, incomplete emptying, or urinary retention. Cancer cells can also enter the lymphatic system and form deposits in regional pelvic lymph nodes. Regional nodal involvement differs anatomically from spread to distant lymph nodes or organs: a tumor need not invade every neighboring structure before distant metastases become detectable. The formal classification of these patterns belongs to anatomical staging rather than symptom description. (cancer.gov)

Bone is the most common site of distant spread. Skeletal deposits can produce persistent pain in the back, hips, pelvis, or ribs, although some deposits cause no symptoms. Metastases remain prostate cancer even when located in bone; they are not primary bone cancers. Damage to affected bone can lead to a pathological fracture, meaning a break through bone weakened by disease rather than one explained solely by substantial trauma. Pain and fractures may impair walking and other daily activities. Distant disease can also involve organs such as the liver and lungs, while advanced cancer may be accompanied by weight loss and marked fatigue. (cancer.gov)

Vertebral metastases can cause spinal cord compression when tumor presses on the spinal cord. Manifestations include back pain, leg weakness or numbness, loss of sensation, and loss of bladder or bowel control; severe compression can cause paralysis. This neurological complication is classified as an oncological emergency because continuing compression can produce lasting neurological damage. It is distinct from urinary retention caused by local obstruction: both can alter bladder function, but one results from interference with neural control and the other from impaired passage of urine through the outlet. (cancer.gov)

Screening and early detection

Screening tests people without symptoms to identify disease before clinical presentation; it differs from investigating urinary symptoms or monitoring previously diagnosed cancer. The principal test is a blood test measuring prostate-specific antigen (PSA), a protein produced by normal and malignant prostate epithelial cells. PSA is prostate-specific, not cancer-specific: benign prostatic hyperplasia and inflammation can also increase its concentration. No threshold reliably separates cancer from noncancer; cancers occur below the historically common cutoff of 4 ng/mL. Digital rectal examination assesses palpable abnormalities through the rectal wall, but has a more limited screening role. The USPSTF’s 2018 recommendation did not endorse it as a screening modality because evidence of benefit was insufficient. (cancer.gov)

A false-positive result suggests cancer when none is present, potentially leading to anxiety, further testing, and biopsy. A false-negative result fails to flag an existing cancer and may delay detection. Overdiagnosis is different: it identifies a genuine cancer that would never have caused symptoms or death during the person’s lifetime. Screening preferentially discovers some slow-growing tumors because they remain detectable for longer. In its 2018 assessment, the USPSTF estimated that 20–50% of screen-detected cancers could represent overdiagnosis, with estimates depending on population and methodology. Downstream harms include biopsy-related bleeding and infection, and unnecessary treatment causing urinary incontinence, erectile dysfunction, or bowel symptoms. These harms may occur promptly, whereas mortality benefits generally take years to emerge. (uspreventiveservicestaskforce.org)

The European Randomized Study of Screening for Prostate Cancer (ERSPC), initiated in 1993, compared repeated PSA screening invitations with a control group not invited for screening. Testing intervals and diagnostic protocols varied between participating countries, commonly using intervals of two or four years. Its 2025 report analyzed 162,236 participants aged 55–69 at randomization across eight European countries. After a median 23 years, prostate-cancer mortality was 13% lower in the screening group: rate ratio 0.87, with a 95% confidence interval of 0.80–0.95. The absolute reduction was 0.22 percentage points, approximately 2.2 fewer prostate-cancer deaths per 1,000 participants. One death was prevented per 456 people invited, while cumulative cancer incidence was 30% higher in the screening group. The increased diagnosis rate illustrates the detection burden accompanying the mortality benefit, but does not itself measure overdiagnosis. (uspreventiveservicestaskforce.org)

The US Prostate, Lung, Colorectal, and Ovarian (PLCO) trial randomized 76,693 men in 1993–2001 to annual PSA testing for six years and rectal examination for four years, or usual care. A 2018 extended analysis, with median mortality follow-up of approximately 17 years, found no statistically significant prostate-cancer mortality reduction. Interpretation differs from ERSPC because substantial screening occurred in PLCO’s control arm: reported annual PSA testing increased from 40% in year one to 52% in year six. This “contamination” reduced the contrast between groups, making PLCO substantially a comparison of organized screening with opportunistic screening rather than screening with no screening. The trials therefore differed in exposure, diagnostic pathways, and follow-up, not merely in their results. (cancer.gov)

Published policies also differ in age and risk thresholds. The USPSTF’s May 8, 2018 recommendation specified individual decision-making at ages 55–69 and recommended against PSA screening from age 70. The AUA/SUO guideline published in 2023 allowed a baseline PSA at ages 45–50 and recommended offering screening at ages 40–45 for increased-risk groups, including people with Black ancestry, relevant inherited mutations, or strong family histories. The American Cancer Society’s guidance, revised November 22, 2023, placed the screening discussion at age 50 for average-risk men with at least ten years’ expected survival, age 45 for African American men or those with a first-degree relative diagnosed before 65, and age 40 for those with multiple first-degree relatives affected early. (uspreventiveservicestaskforce.org)

Informed decision-making addresses the possible reduction in prostate-cancer death alongside false results, overdiagnosis, and consequences of subsequent investigation and treatment. It also considers general health, competing mortality, family history, and the person’s preferences about these outcomes. The USPSTF noted insufficient direct trial evidence to quantify separate screening benefits for African American men or men with a family history; risk-specific policies therefore do not imply equally precise evidence for every subgroup. (uspreventiveservicestaskforce.org)

Diagnostic assessment and tissue confirmation

A newly elevated prostate-specific antigen (PSA) result is usually reassessed before further diagnostic testing. PSA is prostate-specific, not cancer-specific: benign prostatic hyperplasia, prostatitis, urinary retention, recent instrumentation, and ejaculation can increase its concentration. Finasteride and dutasteride can lower PSA, affecting interpretation. Assessment therefore includes previous results, medications, urinary symptoms, examination findings, and family history. The 2023 American Urological Association/Society of Urologic Oncology (AUA/SUO) guideline reported that 25–40% of newly elevated results return to the normal range on retesting. Repeat measurement helps distinguish a persistent elevation from transient or analytical variation; neither a single threshold nor the rate of PSA increase alone establishes a diagnosis. (cancer.org)

Multiparametric magnetic resonance imaging (mpMRI) combines T2-weighted anatomical imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging. These sequences assess tissue structure, water diffusion, and contrast uptake to identify suspicious lesions and guide sampling. The Prostate Imaging Reporting and Data System (PI-RADS), whose version 2.1 was published in 2019, assigns categories from 1, indicating very low likelihood of clinically significant cancer, to 5, indicating very high likelihood; category 3 is equivocal. These are imaging assessments, not histological diagnoses or tumor grades. A negative MRI does not exclude cancer: the 2023 AUA/SUO evidence review estimated a 91% negative predictive value for Grade Group 2 or higher cancer among biopsy-naïve patients with PI-RADS 1–2 findings. Its interpretation depends on the underlying risk and imaging quality. (acr.org)

Tissue confirmation is generally obtained by needle biopsy, with cores examined microscopically by a pathologist. Systematic sampling commonly takes 10–12 cores from distributed locations under ultrasound guidance, whereas MRI-targeted biopsy samples identified lesions using visual localization, MRI–ultrasound software fusion, or direct MRI guidance. Combining targeted and systematic sampling can identify clinically significant tumors missed by either approach alone, although additional sampling also detects more low-grade cancers. In the 2018 PRECISION randomized trial, involving 500 men without a previous biopsy, an MRI-based pathway detected clinically significant cancer in 38%, compared with 26% using standard systematic biopsy; 28% of the MRI-pathway group had nonsuspicious scans and did not undergo biopsy. These results describe the tested diagnostic pathway, not universal sensitivity estimates. (cancer.org)

The sampling strategy and needle-entry route are separate choices. Transrectal biopsy passes through the rectal wall; transperineal biopsy passes through cleaned perineal skin, avoiding traversal of rectal flora. Both can obtain systematic and targeted cores under local anesthesia. Procedural risks include pain, bleeding, urinary retention, and infection, including occasional sepsis; transrectal sampling requires particular attention to antibiotic prophylaxis. In the final 2024 PREVENT trial report by Jim C. Hu and colleagues, infections occurred in none of 372 patients undergoing transperineal biopsy without prophylactic antibiotics, compared with six of 370 patients undergoing transrectal biopsy with culture-directed prophylaxis, or 1.6%. Detection of Grade Group 2–5 cancer was similar between groups. The study concerned first-time biopsies and assessed infections within seven days. (cancer.org)

Supplementary blood and urine biomarkers estimate the probability of cancer, particularly clinically significant disease, and can refine assessment before an initial or repeat biopsy. The Prostate Health Index (PHI) combines total PSA, free PSA, and the precursor form proPSA; the 4Kscore combines total, free, and intact PSA with human kallikrein 2 and clinical factors. Urinary assays include PCA3 and tests incorporating other prostate-associated RNA markers. These tests provide risk estimates rather than demonstrating malignant tissue. Their thresholds trade fewer biopsies against missed or delayed detection, and their value depends on whether the result changes the diagnostic assessment. A negative biopsy also does not exclude unsampled cancer: persistent suspicion can lead to reassessment using PSA, MRI, supplementary tests, and further targeted or systematic sampling. (cancer.org)

Staging and prognostic risk classification

The TNM system records the primary tumor’s extent (T), regional lymph-node involvement (N), and distant metastasis (M). Clinical staging, prefixed c, describes disease before definitive treatment; pathological staging, prefixed p, incorporates examination of surgically removed tissue. Clinical T1 tumors are not palpable, whereas T2 tumors are palpable but confined to the prostate. T3a denotes extraprostatic extension, T3b seminal-vesicle invasion, and T4 fixation or invasion of adjacent structures other than the seminal vesicles, such as the rectum or pelvic wall. N0 indicates no regional nodal metastasis and N1 regional nodal involvement. M1a denotes nonregional lymph-node metastases, M1b bone metastases, and M1c other distant sites, with or without bone involvement. (cancer.gov)

Clinical and pathological categories are not interchangeable. Under the European Association of Urology (EAU) classification, clinical T assignment rests on digital rectal examination, with imaging findings reported separately. A nonpalpable, biopsy-detected tumor is therefore cT1c even when MRI shows a lesion. After prostatectomy, organ-confined cancer is pT2, without the unilateral and bilateral subdivisions used for cT2; pT1 categories do not exist. Examination of removed lymph nodes can establish pN status. Anatomical extent also differs from histological grade: Grade Groups 1–5 describe tumor architecture rather than location. The American Joint Committee on Cancer’s eighth-edition prognostic stage groups, published in 2017, combine TNM, pretreatment prostate-specific antigen (PSA), and Grade Group; regional node-positive M0 disease is stage IVA, whereas distant metastatic disease is stage IVB. (uroweb.org)

Localized-disease risk groups estimate progression or recurrence risk rather than simply restating anatomical stage. In the 2022 AUA/ASTRO classification, low-risk disease requires all three features: PSA below 10 ng/mL, Grade Group 1, and cT1–T2a. Intermediate-risk features include PSA 10 to below 20 ng/mL, Grade Group 2–3, or cT2b–T2c; high-risk features include PSA at least 20 ng/mL, Grade Group 4–5, or cT3. Thus, a nonpalpable tumor can nevertheless be high risk because of its grade or PSA. Biopsy burden helps distinguish favorable from unfavorable intermediate risk: Grade Group 2 with PSA below 10 ng/mL, cT1–T2a, and fewer than 50% positive cores qualifies as favorable intermediate risk. The positive-core proportion is distinct from the percentage of cancer within each core. This guideline counts multiple targeted cores from one MRI lesion as a single core for that calculation. Definitions differ between classification systems, making the named scheme and publication year important. (auanet.org)

Imaging assesses different components of disease extent. MRI provides local soft-tissue detail, including evidence of extraprostatic extension and seminal-vesicle invasion, but cannot exclude microscopic extension. CT evaluates abdominal and pelvic nodes and other sites; nodal assessment based on size and morphology can miss metastases in normal-sized nodes. Technetium-99m bone scintigraphy detects increased bone formation rather than cancer cells directly, so benign skeletal changes can produce abnormal uptake. PSMA PET, usually combined with CT, uses radiolabeled ligands targeting prostate-specific membrane antigen to identify nodal, skeletal, and other lesions. Small metastases may remain undetected, while uptake in benign conditions or other malignancies can produce false-positive findings. (uroweb.org)

In the 2020 proPSMA randomized trial, Michael Hofman and colleagues studied 302 men with high-risk disease being considered for curative-intent surgery or radiotherapy. Gallium-68 PSMA-11 PET/CT achieved 92% accuracy for detecting pelvic nodal or distant metastatic disease, compared with 65% for conventional CT plus bone scanning; sensitivities were 85% and 38%, respectively. These results concern staging accuracy, not a demonstrated survival benefit. (pubmed.ncbi.nlm.nih.gov) More sensitive imaging also produces stage migration: patients previously classified as nonmetastatic may be reassigned after small deposits become visible. Moving patients with relatively limited metastatic burden into a metastatic category can improve apparent outcomes in both categories without changing any individual’s disease course—the Will Rogers phenomenon. Prognostic comparisons therefore depend partly on which imaging methods established the stage. (uroweb.org)

Active surveillance and watchful waiting

Active surveillance defers immediate treatment while preserving the possibility of cure by surgery or radiation therapy if subsequent assessments identify clinically meaningful progression. It therefore involves scheduled testing rather than waiting for symptoms. Watchful waiting has a different objective: management of symptoms or impending complications, usually when limited life expectancy or substantial illness makes curative treatment unsuitable. Follow-up is individualized, and treatment may be introduced to relieve obstruction, pain, or other disease-related problems. Its emphasis is on maintaining quality of life through symptom-directed treatment, including palliative care, rather than detecting every change in tumor grade. (uroweb.org)

Selection for surveillance combines cancer characteristics with competing health risks. Common eligibility criteria include localized Grade Group 1 disease, corresponding to Gleason $3+3=6$, clinical stage cT1c–cT2a, and prostate-specific antigen (PSA) below 10 ng/mL. PSA density—the PSA concentration divided by prostate volume—and the number and extent of involved biopsy cores further characterize risk. Some protocols admit selected Grade Group 2 cancers, corresponding to Gleason $3+4=7$, when pattern 4 and total tumor burden are small; cribriform architecture and intraductal carcinoma generally exclude surveillance. These criteria are not interchangeable across programs. Age alone does not determine the strategy: comorbidity, functional status, estimated life expectancy, and willingness to undergo repeated testing also matter. European Association of Urology guidance uses approximately ten years of life expectancy to distinguish many curative-intent surveillance settings from watchful waiting, and permits transition between them as health circumstances change. (uroweb.org)

Surveillance combines serial PSA measurements, clinical review, prostate examination, magnetic resonance imaging (MRI), and repeat biopsy. As a dated protocol example, the European Association of Urology’s 2023 guidance specified PSA testing at least every six months, digital rectal examination at least annually, and biopsy every two to three years. Timing varies with baseline assessment and subsequent findings. Confirmatory sampling helps identify higher-grade cancer missed by the diagnostic biopsy, particularly when the original assessment did not include MRI guidance. MRI can locate suspicious areas for targeted sampling and assess interval change, but stable imaging does not reliably exclude histological upgrading. The 2022 American Urological Association/American Society for Radiation Oncology guideline consequently treats MRI as an adjunct, not a stand-alone substitute for periodic biopsy. (uroweb.org)

Evidence of progression is evaluated across these measurements rather than inferred from a single PSA result. An increase may prompt repeat testing; persistent rises, new examination abnormalities, or MRI changes can trigger further imaging and biopsy. A short PSA doubling time is a warning signal, not by itself proof that curative treatment is required. Histological findings carry greater weight, including increased pattern 4, progression to Grade Group 3 or higher, or newly detected cribriform or intraductal disease. Greater cancer extent in systematic biopsy cores may also change classification. Apparent “progression” on an early repeat biopsy can represent correction of initial undersampling rather than biological evolution, and a small upgrade to Grade Group 2 does not automatically end surveillance in every protocol. (auanet.org)

Long-term studies quantify the trade-off between avoiding unnecessary treatment and detecting consequential disease. In the prospective Canary Prostate Active Surveillance Study, reported in 2024, 2,155 men were followed for a median of 7.2 years; 90% initially had Grade Group 1 cancer. Estimated ten-year incidences were 43% for grade reclassification, 49% for treatment, 1.4% for metastasis, and 0.1% for prostate-cancer death. These observational outcomes describe a selected, monitored population, not an untreated natural history. In contrast, Freddie Hamdy and colleagues’ 2023 report from the ProtecT randomized trial found fifteen-year prostate-cancer mortality of 3.1% with active monitoring, 2.2% with prostatectomy, and 2.9% with radiotherapy, without a statistically significant difference; metastases occurred in 9.4%, 4.7%, and 5.0%, respectively. ProtecT’s monitoring was predominantly PSA-based and included a broader risk mix, so it should not be equated with contemporary MRI- and biopsy-based surveillance. (jamanetwork.com)

Local treatment with surgery and radiation

Radical prostatectomy removes the entire prostate and seminal vesicles, with pelvic lymph-node dissection in selected cases. Open surgery uses a larger incision, usually in the lower abdomen; laparoscopic surgery uses a camera and instruments introduced through several small incisions. Robot-assisted laparoscopy uses surgeon-controlled robotic instruments rather than an independently operating robot. These approaches perform the same cancer-removing operation. They differ fundamentally from transurethral resection of the prostate (TURP), which removes obstructing tissue through the urethra to improve urine flow. TURP is used for benign prostatic hyperplasia or cancer-associated obstruction, but does not remove the whole gland and is not equivalent to radical prostatectomy as definitive cancer treatment. (cancer.gov)

External-beam radiation therapy (EBRT) delivers radiation from outside the body to the prostate and, depending on disease extent and risk, adjacent tissues or pelvic nodes. Intensity-modulated radiation therapy and volumetric-modulated arc therapy shape the dose distribution around the target while limiting exposure of the rectum and bladder. Image-guided delivery uses techniques such as implanted gold markers or cone-beam computed tomography to check prostate position and correct for movement. Fractionation divides the prescribed dose among treatment sessions: moderate hypofractionation uses larger doses per session and fewer sessions than conventional fractionation, while ultrahypofractionation uses still fewer, higher-dose treatments. (uroweb.org)

The CHHiP randomized trial enrolled 3,216 men with nonmetastatic disease and compared 74 gray (Gy) in 37 fractions with 60 Gy in 20 fractions and 57 Gy in 19 fractions. Five-year freedom from biochemical or clinical treatment failure was 88.3%, 90.6%, and 85.9%, respectively. The 60-Gy schedule met the trial’s noninferiority criterion against conventional treatment; the 57-Gy schedule did not. These findings illustrate that shortened schedules require validation of the particular dose and fractionation, rather than an assumption that all shorter courses are interchangeable. Five-fraction stereotactic treatment has also been studied: the PACE-B trial compared 36.25 Gy in five fractions with conventional or moderately hypofractionated radiation in men with T1–T2 disease, Gleason scores no higher than 3+4, and PSA no higher than 20 ng/mL, without androgen-deprivation therapy. (cancer.gov)

Brachytherapy places radiation sources within the prostate. Low-dose-rate treatment leaves radioactive seeds permanently implanted, with radiation delivered as the isotope decays; high-dose-rate treatment temporarily introduces a source through catheters and removes it after treatment. Brachytherapy can be used alone in selected localized cancers or as a “boost” accompanying EBRT. The 2022 AUA/ASTRO guideline identifies permanent low-dose-rate implants, temporary high-dose-rate implants, and appropriately dosed hypofractionated EBRT as established radiation options for low- or favorable intermediate-risk disease. For unfavorable intermediate- or high-risk disease, combined EBRT and brachytherapy is an option alongside a risk-appropriate course of hormonal treatment. (cancer.gov)

Combining local radiation with androgen-deprivation therapy (ADT) depends on the disease-risk category. The 2022 AUA/ASTRO guideline does not routinely include ADT with radiation for low- or favorable intermediate-risk cancer, but specifies four to six months for unfavorable intermediate-risk cancer and 18–36 months for high-risk cancer. These are published treatment categories, not interchangeable regimens for every localized tumor. Radiation may also be used after prostatectomy for selected adverse pathological findings or subsequent recurrence; the indications and timing belong to postoperative and salvage management. (auanet.org)

Focal ablation destroys a selected tumor-bearing region rather than removing or irradiating the entire gland. Cryotherapy uses freezing to damage cell membranes and the local microcirculation; high-intensity focused ultrasound produces thermal and mechanical tissue injury, including coagulative necrosis. Both techniques can also be applied to the whole gland, which is distinct from focal treatment. Their evidence base is not equivalent to that of prostatectomy or established radiation regimens: many studies are nonrandomized, use differing definitions of treatment failure, and have limited follow-up. European Association of Urology guidance confines focal HIFU or cryotherapy to prospective registries, while the 2022 AUA/ASTRO guideline emphasizes the lack of high-quality comparative evidence and excludes high-risk ablation outside clinical trials. Residual or recurrent cancer can occur outside the treated region, making imaging and repeat biopsy important components of assessment. (uroweb.org)

Androgen deprivation and hormonal medicines

Androgen deprivation therapy (ADT) suppresses testicular testosterone production rather than removing the prostate or directly destroying tumor tissue. Bilateral orchiectomy permanently removes the principal source of circulating testosterone. Medical suppression acts on the pituitary–testicular hormonal axis: gonadotropin-releasing hormone (GnRH) agonists, including leuprolide, goserelin, and triptorelin, initially stimulate pituitary receptors but subsequently suppress luteinizing hormone secretion through sustained stimulation. GnRH antagonists block these receptors directly; examples are injectable degarelix and oral relugolix. Medical suppression can be reversible, although testosterone recovery after withdrawal depends on age, pretreatment levels, and treatment duration. (cancer.gov)

The initial testosterone surge caused by a GnRH agonist is termed treatment flare. It can transiently worsen bone pain, urinary obstruction, or spinal cord compression in patients with advanced disease. A short course of an androgen-receptor blocker, such as bicalutamide, may accompany agonist initiation to reduce the clinical effects of this surge. GnRH antagonists suppress testosterone without the initial flare. Receptor blockade is mechanistically distinct from ADT: it interferes with androgen action at the tumor-cell receptor rather than primarily lowering circulating testosterone. Combining the two therefore targets both androgen availability and the response to remaining androgens. (cancer.gov)

Abiraterone inhibits androgen synthesis rather than directly blocking the receptor. Its active form inhibits CYP17A1, an enzyme involved in steroid biosynthesis in testicular, adrenal, and tumor tissues. Abiraterone acetate with prednisone is used for metastatic castration-resistant disease and high-risk metastatic castration-sensitive disease; testicular suppression is maintained by medical ADT or prior orchiectomy. Prednisone accompanies treatment to reduce adverse consequences of altered adrenal steroid production. Thus, adding abiraterone does not mean that the underlying castration treatment has been discontinued. (cancer.gov)

Enzalutamide, apalutamide, and darolutamide are oral androgen-receptor inhibitors with overlapping but nonidentical treatment contexts. All three have demonstrated benefit in nonmetastatic castration-resistant disease while ADT continues; they also have roles in metastatic castration-sensitive disease. Enzalutamide additionally treats metastatic castration-resistant disease. On November 16, 2023, the US Food and Drug Administration approved enzalutamide, with or without a GnRH analogue, for nonmetastatic castration-sensitive disease with high-risk biochemical recurrence; the supporting EMBARK trial enrolled patients with a prostate-specific antigen (PSA) doubling time of nine months or less. On June 3, 2025, the FDA expanded darolutamide’s metastatic castration-sensitive indication beyond its earlier docetaxel-containing regimen. In the supporting ARANOTE trial, all participants received a GnRH analogue or had undergone orchiectomy: omission of chemotherapy did not mean omission of ADT. (cancer.gov)

Continuous suppression maintains treatment without planned breaks; intermittent suppression alternates treatment periods with monitored pauses and predefined restart criteria. Evidence depends on disease setting. Juanita Crook and colleagues’ 2012 randomized trial enrolled 1,386 patients with rising PSA after radiotherapy and no metastatic disease. Intermittent treatment, using eight-month cycles, met the trial’s noninferiority criterion for overall survival: median survival was 8.8 versus 9.1 years with continuous treatment, with improvements in some quality-of-life measures. By contrast, Maha Hussain and colleagues’ 2013 metastatic-disease trial did not establish noninferiority; median survival was 5.1 versus 5.8 years, respectively. These findings do not establish that the two schedules are interchangeable across disease states. (nejm.org)

Castration resistance requires progression despite a measured castrate testosterone concentration, conventionally below $50\ \mathrm{ng/dL}$, approximately $1.7\ \mathrm{nmol/L}$. Many patients achieve levels below $20\ \mathrm{ng/dL}$, but inadequate suppression or testosterone breakthrough can occur during medical treatment. A rising PSA alone therefore does not establish castration resistance without confirming testosterone suppression. Castration-resistant tumors can remain responsive to further androgen-pathway inhibition, and ADT generally continues when these additional medicines are introduced. (uroweb.org)

Systemic treatment of advanced disease

Metastatic hormone-sensitive prostate cancer (mHSPC) has spread to distant sites but remains responsive to androgen suppression. Castration-resistant disease progresses despite suppressed testosterone: nonmetastatic castration-resistant prostate cancer (nmCRPC) has no distant metastases demonstrated on the imaging used for classification, whereas metastatic castration-resistant prostate cancer (mCRPC) has demonstrable metastatic disease. Castration resistance does not imply complete independence from androgen signaling; androgen-deprivation therapy (ADT) generally continues alongside subsequent systemic treatments. Apalutamide, enzalutamide, and darolutamide have established roles in nmCRPC, while chemotherapy, molecularly targeted treatments, radiopharmaceuticals, and selected immunotherapies principally address metastatic disease. (cancer.gov)

For mHSPC, treatment intensification combines ADT with an androgen-receptor pathway inhibitor, with docetaxel incorporated into established triplet regimens for selected patients. Docetaxel is a taxane chemotherapy drug that stabilizes microtubules and disrupts cell division. In the 2022 ARASENS randomized trial, adding darolutamide to ADT and docetaxel reduced the hazard of death relative to ADT and docetaxel alone: the hazard ratio was 0.68, with a 95% confidence interval of 0.57–0.80. This comparison established the benefit of that specific triplet, rather than the superiority of every possible three-drug combination. Molecular selection has also extended into hormone-sensitive disease: on December 12, 2025, the US Food and Drug Administration (FDA) approved niraparib–abiraterone with prednisone for BRCA2-mutated metastatic castration-sensitive disease identified by an approved test. (cancer.gov)

Docetaxel also prolongs survival in mCRPC, commonly administered with prednisone. Cabazitaxel, another taxane, has an established role after previous docetaxel treatment. Treatment sequence matters: the 2019 CARD trial enrolled patients previously treated with docetaxel whose disease had progressed within 12 months on abiraterone or enzalutamide. Cabazitaxel produced longer median imaging-based progression-free survival than switching to the alternative androgen-signaling inhibitor—8.0 versus 3.7 months—and longer median overall survival, 13.6 versus 11.0 months. These findings apply to the trial’s previously treated population, not to all patients starting systemic therapy. (cancer.gov)

PARP inhibitors interfere with DNA repair, creating particular vulnerability in tumors with defective homologous-recombination repair (HRR). Eligibility depends on the drug, pathogenic alteration, combination, and previous treatment. US-approved mCRPC examples include olaparib–abiraterone for BRCA-altered disease, talazoparib–enzalutamide for specified HRR gene mutations, and rucaparib for BRCA-mutated disease previously treated with an androgen-receptor-directed therapy. Different repair alterations do not predict equal benefit. In the FDA’s 2023 TALAPRO-2 analysis, the exploratory hazard ratio for radiographic progression or death was 0.20 in BRCA-mutated tumors but 0.72 in non-BRCA HRR-mutated tumors; the latter confidence interval, 0.49–1.07, included no difference. Thus, an alteration in a broadly defined repair pathway is not interchangeable with a validated predictive biomarker. (pmc.ncbi.nlm.nih.gov)

Lutetium-177 vipivotide tetraxetan links a beta-emitting radionuclide to a ligand targeting prostate-specific membrane antigen (PSMA), delivering radiation to PSMA-expressing lesions. Eligibility requires PSMA-positive disease demonstrated with an approved PET agent. Initially approved in the United States in 2022 after androgen-receptor pathway inhibition and taxane chemotherapy, its indication expanded on March 28, 2025, to include previously ARPI-treated mCRPC when delaying taxane chemotherapy is considered appropriate. Radium-223 has a different target: it mimics calcium, accumulates in bone mineral at sites of increased turnover, and emits short-range alpha particles. Its indication concerns castration-resistant disease with symptomatic bone metastases and no known visceral metastases, not PSMA expression. (cancer.gov)

Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic mCRPC. Collected immune cells are exposed outside the body to a fusion protein containing prostatic acid phosphatase and granulocyte–macrophage colony-stimulating factor, then reinfused to stimulate an antitumor immune response. Pembrolizumab instead blocks the PD-1 immune checkpoint. Its tumor-agnostic eligibility can encompass advanced prostate cancers with microsatellite instability-high status, deficient DNA mismatch repair, or high tumor mutational burden, defined as at least 10 mutations per megabase by an approved test. These indications require progression after prior treatment and no satisfactory alternative options; a BRCA alteration alone does not establish checkpoint-inhibitor eligibility. (cancer.gov)

Follow-up, recurrence, and prognosis

Serial prostate-specific antigen (PSA) measurements are central to follow-up after treatment intended to eradicate the cancer. After radical prostatectomy, PSA is expected to become undetectable within approximately two months because the principal PSA-producing organ has been removed. After radiation therapy, benign prostate tissue remains, and PSA generally declines more slowly; its lowest value, or nadir, may not be reached for three years or longer. The European Association of Urology describes PSA testing every six months for the first three years after local treatment and annually thereafter, while acknowledging limited evidence for an optimal interval. Follow-up also assesses symptoms and treatment complications; routine imaging after curative local treatment is generally reserved for suspected recurrence when the result could affect management. (uroweb.org)

Biochemical recurrence denotes a treatment-specific PSA rise, not necessarily a tumor demonstrated by examination, biopsy, or imaging. A commonly used American Urological Association definition after prostatectomy is PSA at least $0.2\,\mathrm{ng/mL}$, confirmed by a subsequent value above $0.2\,\mathrm{ng/mL}$. This differs from PSA persistence, in which PSA never becomes undetectable after surgery; studies commonly define persistence as at least $0.1\,\mathrm{ng/mL}$ four to eight weeks postoperatively. Persistence can reflect residual local cancer or occult metastatic disease, although benign residual tissue and testing too early can complicate interpretation. A very low detectable result from an ultrasensitive assay is therefore not equivalent to confirmed recurrence. Short PSA doubling time, high Grade Group, and a short interval from treatment to recurrence identify greater risks of subsequent progression. (auanet.org)

After radiation, the 2006 RTOG–ASTRO Phoenix definition identifies biochemical failure as PSA rising at least $2\,\mathrm{ng/mL}$ above the post-treatment nadir, including when radiation was combined with androgen deprivation. The threshold differs from that used after surgery because surviving benign cells continue to produce PSA. A PSA bounce is a temporary rise followed by a spontaneous decline, often within the first couple of years after external-beam radiation or brachytherapy; it does not by itself establish recurrence. Serial trends distinguish this fluctuation from sustained increases. Biochemical relapse may precede clinically apparent disease by years, and some patients remain free of symptoms or demonstrable metastases for prolonged periods. (uroweb.org)

Assessment of suspected relapse integrates PSA kinetics, original pathology, previous treatment, symptoms, and imaging. PSMA-targeted positron emission tomography can identify disease in the prostate bed, pelvic lymph nodes, or distant sites; pelvic magnetic resonance imaging can further assess local abnormalities. Negative imaging at a low PSA does not exclude microscopic disease. Salvage treatment seeks to control recurrence after initial definitive therapy: after prostatectomy, prostate-bed radiation can retain curative potential. The 2024 AUA/ASTRO/SUO guideline emphasizes greater effectiveness at lower PSA levels and specifies delivery at PSA no higher than $0.5\,\mathrm{ng/mL}$ when salvage radiation is selected; a negative PET scan alone is not grounds to withhold it. Hormonal treatment may accompany radiation according to progression risk. After primary radiation, selected patients with biopsy-confirmed local recurrence may undergo salvage prostatectomy, ablation, or reirradiation, with attention to increased urinary and other treatment risks. Demonstrated distant disease instead changes the principal treatment context to systemic management. (auanet.org)

US SEER data for diagnoses in 2016–2022 report five-year relative survival of 100.0% for localized disease, 100.0% for regional disease, and 40.1% for distant disease. These are categories of extent at initial diagnosis, not survival estimates starting at recurrence. Relative survival compares observed survival with expected survival in a comparable general population; it does not mean that every patient with localized cancer survives or is cured. Cancer-specific mortality counts deaths attributed to prostate cancer, whereas overall mortality includes every cause. Competing mortality—from cardiovascular disease, other cancers, and other conditions—is particularly important in an older population. Registry averages cannot determine an individual outcome because tumor grade, recurrence kinetics, metastatic burden, age, comorbidity, and treatment response vary substantially among patients. (seer.cancer.gov)

Treatment effects and survivorship

Radical prostatectomy can disrupt the urinary sphincter and its supporting structures, producing urinary incontinence, particularly leakage during coughing, lifting, or exercise. Continence often improves during recovery, but persistent leakage may require pads or further treatment. Injury to the nerves beside the prostate can cause erectile dysfunction; nerve-sparing surgery preserves these structures when technically and oncologically feasible, but does not guarantee recovery. Removal of the prostate and seminal vesicles eliminates seminal ejaculation, although orgasm may remain possible. This “dry orgasm” is distinct from erectile dysfunction: a person may experience orgasm without an erection or ejaculate. Natural conception through intercourse is no longer possible after radical prostatectomy, even if the testes continue producing sperm; sperm banking and assisted reproduction are separate fertility-preservation pathways. Pelvic radiation can also impair fertility and damage nerves or blood vessels involved in erections. (cancer.gov)

Radiation therapy exposes adjacent bladder, urethral, and rectal tissues as well as the tumor. Early toxicity, occurring during treatment or shortly afterward, commonly includes urinary frequency, urgency, burning urination, diarrhea, rectal discomfort, and bowel urgency. These effects reflect irritation and inflammation of healthy tissues and often diminish after treatment ends. Late toxicity may first appear months or years later: chronic radiation proctopathy can cause rectal bleeding, mucus discharge, and fecal leakage, while bladder injury can cause hematuria and persistent urinary symptoms. Urethral narrowing can obstruct urination. Erectile impairment after radiation may develop gradually rather than immediately. Late effects are therefore not simply prolonged versions of acute symptoms, and their likelihood depends on the irradiated tissues, dose, and treatment technique. (cancer.gov)

Androgen deprivation affects organs beyond the prostate because androgens participate in sexual function, bone maintenance, muscle development, and metabolism. Established effects include hot flashes, reduced sexual desire, erectile dysfunction, loss of bone mineral density, increased fracture risk, reduced muscle mass and strength, increased body fat, insulin resistance, and fatigue. Sustained bone loss can lead to osteoporosis; it is mechanistically distinct from skeletal damage caused by metastases. Treatment duration influences the burden of adverse effects. After medical androgen deprivation stops, testosterone and sexual function may recover, but recovery can be incomplete, especially after prolonged treatment or at older ages; established bone loss may persist. Exercise-based rehabilitation and medicines that preserve bone density have been studied to address these treatment-associated changes. (cancer.gov)

Patient-reported outcomes measure symptoms, function, and the extent to which problems interfere with life, rather than relying only on clinician-recorded complications. In the 2023 twelve-year report from the ProtecT randomized controlled trial, involving 1,643 participants assigned to prostatectomy, radiotherapy with neoadjuvant androgen deprivation, or active monitoring, daily pad use for urinary leakage affected 18–24% of the prostatectomy group during years 7–12, compared with 3–8% after radiotherapy and 9–11% with active monitoring. At seven years, erections sufficient for intercourse were reported by 18%, 27%, and 30%, respectively. Despite these domain-specific differences, generic quality-of-life scores were similar between groups. The monitoring group was not an untreated comparator throughout follow-up: 59% had received radical treatment by twelve years. (evidence.nejm.org)

Survivorship services address functional limitations alongside mental health, relationships, and everyday activities. Continence rehabilitation includes pelvic-floor muscle training; persistent stress incontinence may be treated with a male sling or artificial urinary sphincter. Erectile-dysfunction treatment includes oral medicines, injections, vacuum devices, and penile prostheses, which address erections rather than restoring ejaculation or necessarily reversing androgen-deprivation-related loss of desire. Psychological burdens can include anxiety, depressed mood, altered body image, and distress over sexual changes. Partners may experience changes in intimacy and additional caregiving, household, and employment responsibilities. Counseling, sexual-health services, physical rehabilitation, and coordinated follow-up provide distinct components of survivorship care. (auanet.org)

Supportive and palliative care

Palliative care addresses symptoms, treatment burdens, and psychological, social, and spiritual distress; it can accompany disease-directed treatment from diagnosis onward. In advanced prostate cancer, hormonal medicines, chemotherapy, or radiation may both control cancer and relieve symptoms, while specialist palliative services provide additional symptom management and support. Palliative care is not synonymous with hospice: hospice concentrates on comfort near the end of life, whereas palliative care does not require discontinuation of life-prolonging treatment. Its objectives include preserving function and quality of life, rather than measuring benefit solely through tumor response or survival. (cancer.gov)

Management of pain distinguishes skeletal pain, nerve-related pain, and pain caused by treatment or other disorders. Analgesic regimens may combine nonopioid medicines with opioids such as morphine or oxycodone; persistent pain and breakthrough episodes are assessed separately. Neuropathic pain may require additional agents, including gabapentin. Opioid treatment also entails monitoring sedation and other adverse effects and managing constipation, because opioids reduce intestinal motility. Localized painful bone metastases can respond to external-beam radiation therapy. In the RTOG-9714 randomized trial, a single 8-Gy treatment produced pain relief and quality-of-life benefits similar to ten 3-Gy treatments, illustrating how shorter treatment schedules can reduce the burden of attending hospital. (cancer.gov)

Skeletal complications require more than analgesia. Assessment of spinal stability and fracture risk can identify lesions requiring stabilization or other surgical intervention. Metastatic spinal cord compression is an oncological emergency because neurological injury may become irreversible. NICE’s 2023 guideline specifies urgent MRI within 24 hours for suspected compression with neurological signs or symptoms; management includes corticosteroids and, according to clinical circumstances, decompressive surgery or urgent radiotherapy. These interventions seek to preserve mobility and neurological function as well as relieve pain. (nice.org.uk)

Prevention of androgen-deprivation-associated osteoporosis is distinct from prevention of complications caused by bone metastases. The former concerns generalized loss of bone strength and fragility fractures, including in patients without metastatic disease. In Matthew R. Smith and colleagues’ 2009 randomized trial of 1,468 men receiving androgen deprivation for nonmetastatic cancer, denosumab 60 mg every six months reduced new vertebral fractures at three years from 3.9% to 1.5%. By contrast, bone-metastasis treatment targets skeletal-related events: pathological fractures, spinal cord compression, and the need for bone radiation or surgery. Denosumab inhibits RANK ligand signaling involved in osteoclast-mediated bone resorption; zoledronic acid is a bisphosphonate that inhibits osteoclast activity. In Karim Fizazi and colleagues’ 2011 trial in metastatic castration-resistant disease, median time to the first skeletal-related event was 20.7 months with denosumab versus 17.1 months with zoledronic acid, without a survival difference. Their use entails attention to hypocalcemia, osteonecrosis of the jaw, and, for zoledronic acid, renal function. (pubmed.ncbi.nlm.nih.gov)

Urinary palliation depends on the level of obstruction. Tumor-related urethral obstruction may be relieved by transurethral prostate resection or radiation; these procedures have a symptom-relieving purpose distinct from radical prostatectomy. Obstruction of the upper urinary tract may require a ureteric stent or percutaneous nephrostomy to drain urine. NICE guidance explicitly includes discussion of the option of no drainage intervention when weighing its benefits and burdens. Other supportive needs include management of nausea, constipation, fatigue, nutritional difficulties, and emotional distress, assessed alongside their potentially treatable causes. (cancer.gov)

Coordination brings together oncology, urology, radiation oncology, palliative medicine, nursing, pharmacy, social work, and rehabilitation services. Dietitians, psychologists, and spiritual-care practitioners address additional needs, while caregivers may require practical and emotional support. Goals-of-care discussions establish the patient’s priorities, understanding of prognosis, and preferences concerning treatment burdens, hospitalization, and end-of-life care. Advance directives and communication among clinicians, patients, and caregivers help translate these preferences into a shared care plan across outpatient, hospital, and home settings. (cancer.gov)

Prevention and risk-reduction evidence

Primary prevention seeks to reduce the occurrence of cancer; screening detects disease that already exists, while treatment may reduce progression or death after diagnosis. These objectives require different measures of effectiveness. A reduction in biopsy-detected prostate cancer does not necessarily establish prevention of lethal disease: diagnosis rates depend partly on testing, biopsy protocols, and the detection of small tumors that might never become symptomatic. Prevention studies therefore distinguish effects on incidence from effects on prostate-cancer mortality and overall survival. (cancer.gov)

Finasteride and dutasteride inhibit 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone, reducing androgen stimulation within the prostate. Both are also used for benign prostatic hyperplasia. In the Prostate Cancer Prevention Trial (PCPT), led by Ian Thompson and first reported in 2003, 18,882 men aged at least 55 years were assigned to finasteride, 5 mg daily, or placebo for seven years. Among participants with evaluable cancer status in the original analysis, cancer was found in 18.4% versus 24.4%, an absolute difference of 6 percentage points and a relative reduction of 24.8%. Much of the reduction involved low-grade disease. The original excess of high-grade diagnoses prompted concern, although subsequent analyses showed that prostate shrinkage and improved detection could contribute to this finding. (cancer.gov)

Long-term PCPT follow-up reported in 2019 did not demonstrate a statistically significant mortality benefit. After a median 18.4 years, there were 42 prostate-cancer deaths in the finasteride group and 56 in the placebo group; the hazard ratio was 0.75, with a 95% confidence interval of 0.50–1.12. These results did not substantiate the feared increase in prostate-cancer mortality, but neither did they establish that finasteride prevents death from the disease. Sexual adverse effects and breast enlargement are additional considerations in interpreting its prevention evidence. (med-fom-urlgsci.sites.olt.ubc.ca)

The REDUCE trial, reported by Gerald Andriole and colleagues in 2010, tested dutasteride, 0.5 mg daily, for four years in men aged 50–75 with elevated PSA and a recent negative biopsy. Scheduled biopsies were performed at years two and four. Among 6,729 men undergoing biopsy or prostate surgery, cancer was detected in 659 of 3,305 dutasteride recipients and 858 of 3,424 placebo recipients—a relative reduction of 22.8%. There was no significant reduction in Gleason 7–10 cancers overall; during years three and four, Gleason 8–10 tumors numbered 12 versus one. REDUCE established fewer biopsy-detected diagnoses, not reduced prostate-cancer mortality. (pubmed.ncbi.nlm.nih.gov)

The Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized controlled trial involving more than 35,000 men, tested selenium, 200 micrograms daily, vitamin E, 400 IU daily, their combination, or placebo. Supplement use stopped in October 2008 after review found no preventive benefit. Follow-up published in 2011 showed a statistically significant 17% relative increase in prostate-cancer diagnoses with vitamin E alone: approximately 76 rather than 65 cases per 1,000 men over seven years. Neither selenium alone nor the combination reduced risk. These findings concern the tested supplement formulations and doses, not proof that ordinary dietary intake has the same effects. (cancer.gov)

Evidence for dietary patterns, lycopene, and other proposed nutritional interventions remains insufficient to establish prostate-cancer prevention. Physical-activity findings also vary: a Swedish prospective study of 45,887 men reported lower incidence with greater lifetime activity, whereas a US cohort of 72,174 men found no significant association with overall incidence, although aggressive disease was less frequent in the most active group. Such observational associations do not establish causation. Differences in PSA testing, correlated lifestyle factors, confounding, and questionnaire-based exposure measurement complicate interpretation; effects on total diagnoses, aggressive disease, and outcomes after diagnosis cannot be treated as interchangeable. (cancer.gov)

Historical development of knowledge and treatment

Charles B. Huggins’s investigations around 1940 connected normal prostatic function with the hormonal responsiveness of malignant tissue. Experiments with Philip J. Clark examined how castration and estrogen administration altered the canine prostate; Huggins subsequently investigated hormonal manipulation in men with advanced disease. In April 1941, Huggins and Clarence V. Hodges published their landmark study in Cancer Research. They used serum acid phosphatase, an enzyme associated with disseminated prostatic carcinoma, as a measurable indicator of disease activity. Levels fell after removal of the testes or estrogen administration, whereas androgen injections could increase them. A companion clinical paper by Huggins, R. E. Stevens Jr., and Hodges, published in August 1941, documented improvement in patients with advanced carcinoma after castration. These findings established that prostate cancer could retain dependence on hormonal stimulation despite its malignant and metastatic character. (rupress.org)

The 1966 Nobel Prize in Physiology or Medicine recognized Huggins “for his discoveries concerning hormonal treatment of prostatic cancer.” He received half of the prize; the other half went to Peyton Rous for the separate discovery of tumour-inducing viruses. The recognition concerned the principle of controlling cancer through alteration of its hormonal environment, rather than discovery of a surgical technique or a universally curative treatment. Hormonal responses in advanced prostate cancer did not generally constitute eradication of the disease, and subsequent progression remained a limitation of androgen deprivation. (nobelprize.org)

Histological assessment became more reproducible through Donald F. Gleason’s classification, published in 1966. Developed from material collected through Veterans Administration hospitals, the system classified cancers by glandular architecture rather than primarily by individual cellular appearance. Its original development involved specimens from 270 patients. Because cancers commonly contained more than one architectural pattern, two predominant patterns were recorded and combined into a score. Gleason and George T. Mellinger’s 1974 publication examined prognosis using combined histological grading and clinical staging. This work made Gleason grading a framework for relating microscopic structure to clinical outcomes, with later revisions adapting it to changes in diagnostic sampling and pathological interpretation. (pubmed.ncbi.nlm.nih.gov)

The development of prostate-specific antigen (PSA) testing provided a different means of detecting and monitoring disease. In 1979, Ming C. Wang, L. A. Valenzuela, Gerald P. Murphy, and T. Ming Chu reported purification of a prostate-specific antigen distinct from acid phosphatase. Their experiments detected it in normal, benign enlarged, and malignant prostate tissue, demonstrating tissue specificity rather than cancer specificity. In 1987, Thomas A. Stamey and colleagues compared PSA with prostatic acid phosphatase in 2,200 serum samples from 699 patients, including 378 with prostate cancer. PSA testing spread into early-detection practice in the late 1980s, accompanied by abrupt increases in recorded incidence. Its historical importance therefore included both improved biochemical monitoring and a transformation in which cancers were diagnosed. (pubmed.ncbi.nlm.nih.gov)

Anatomical research also changed local treatment. Patrick C. Walsh and Pieter J. Donker’s 1982 study traced the pelvic autonomic nerves supplying the erectile tissues and identified points where radical prostatectomy could injure them, particularly during division of the lateral pedicle and dissection near the urethral apex. This provided an anatomical basis for nerve-sparing modifications of surgery, making preservation of sexual function an explicit technical objective alongside tumour removal. The paper distinguished nerve injury from arterial insufficiency and psychological explanations of postoperative erectile dysfunction. (doi.org)

Later milestones extended treatment beyond hormonal suppression alone. The 2004 TAX 327 randomized trial, involving 1,006 men with metastatic hormone-refractory disease, demonstrated longer median survival with docetaxel every three weeks plus prednisone than with mitoxantrone plus prednisone: 18.9 versus 16.5 months. The US Food and Drug Administration approved that docetaxel combination on May 19, 2004. In 2021, the VISION trial demonstrated a survival benefit from lutetium-177–PSMA-617 in previously treated, PSMA-positive metastatic castration-resistant disease. Selection by PSMA imaging and delivery of radiation through a PSMA-binding compound represented a further milestone linking a tumour-associated molecular target to systemic treatment. (nejm.org)

Research methods and developing approaches

Prostate cancer randomized controlled trials distinguish survival, progression, and patient experience as separate outcomes. Overall survival measures time from randomization to death from any cause; it avoids uncertainty in assigning cause of death but can require prolonged follow-up in localized disease. Metastasis-free survival generally measures time to distant metastasis or death, whereas radiographic progression-free survival measures time to imaging-defined progression or death. Biochemical progression, radiographic progression, and symptomatic deterioration are not interchangeable: a treatment may alter prostate-specific antigen (PSA) without producing a corresponding survival benefit. The 2016 Prostate Cancer Clinical Trials Working Group 3 framework therefore separates PSA, imaging, and clinical outcomes. Patient-reported outcomes assess effects such as pain, physical functioning, and treatment-related symptoms directly, complementing clinician-recorded toxicity and survival measurements. (pmc.ncbi.nlm.nih.gov)

Intermediate endpoints can shorten trials only when their relationship to survival has been validated in the relevant setting. In 2017, the ICECaP collaboration assembled individual-patient data from 28 trials involving 28,905 men with localized disease; the metastasis-free-survival analysis included 12,712 participants from 19 trials. It demonstrated a strong relationship between treatment effects on metastasis-free and overall survival, supporting metastasis-free survival as a surrogate endpoint in that setting. This does not establish every progression measure as a survival surrogate or automatically extend the finding to all metastatic populations, treatments, and imaging methods. The underlying trials enrolled patients between 1987 and 2011, making subsequent changes in treatment and disease detection important considerations. (ascopubs.org)

Molecular classifiers seek to identify clinically consequential disease more accurately than clinical stage, PSA, and histological grade alone. Decipher, for example, combines the expression of 22 genes measured in tumor tissue into a risk score. A 2023 ancillary analysis of the randomized NRG Oncology/RTOG 0126 radiation trial examined 215 evaluable biopsy samples with median follow-up of 12.8 years. Ten-year distant-metastasis rates were 4% in the classifier’s low-risk group and 16% in its high-risk group. Such analyses establish prognostic information, but demonstrating that a score predicts benefit from a particular treatment is a separate question. Biomarker-guided randomized designs address that distinction: NRG-GU009/PREDICT-RT was designed to compare 12 versus 24 months of androgen deprivation in lower-genomic-risk disease and to test additional apalutamide in the higher-risk cohort. These experimental strategies are not established merely because the classifier is commercially available. (pubmed.ncbi.nlm.nih.gov)

Circulating tumor DNA research uses tumor-derived DNA fragments in plasma to investigate molecular alterations without repeatedly sampling metastatic lesions. Serial sequencing can reveal changing clone frequencies and resistance-associated alterations; a 2014 study demonstrated spatially and temporally heterogeneous resistant clones under treatment selection pressure. Important analytical limitations remain. Localized tumors often release little detectable tumor DNA, so a negative plasma result does not exclude cancer. Moreover, mutations detected in plasma can originate from blood-cell clones rather than the tumor. A 2020 prostate cancer study showed that clonal hematopoiesis could confound identification of DNA-repair alterations relevant to PARP-inhibitor selection, supporting paired blood-cell analysis to distinguish their origin. (pubmed.ncbi.nlm.nih.gov)

Treatment-sequencing studies test whether resistance to one agent changes the effectiveness of the next. The 2019 CARD trial compared cabazitaxel with switching between abiraterone and enzalutamide in men previously treated with docetaxel whose disease had progressed within 12 months on an androgen-signaling inhibitor. Median imaging-based progression-free survival was 8.0 versus 3.7 months, favoring cabazitaxel. This was evidence for a defined treatment sequence, not proof that one sequence is optimal for every disease state. Biomarker-selected combination trials similarly require randomized comparisons to establish whether molecular selection improves outcomes sufficiently to justify additional toxicity. (nejm.org)

Evidence applicability depends on recruitment and measurement as well as statistical significance. An analysis of 39 predominantly US phase III trials from 2003–2014 found underenrollment of African American men in metastatic-disease trials and persistent underenrollment of Latino and Asian American men. Predictive tools therefore require external testing across populations and clinical settings, rather than relying exclusively on their development datasets. Changing imaging sensitivity creates another limitation: PSMA-targeted PET detects disease missed by conventional imaging, potentially shifting patients between “nonmetastatic” and “metastatic” categories without any biological change. Trials must consequently specify imaging methods and progression definitions; comparisons across imaging eras can otherwise mistake earlier detection for a change in disease trajectory. (pubmed.ncbi.nlm.nih.gov)

References

1. Understanding Prostate Changes - NCIcancer.gov
2. Anatomy - SEER Trainingtraining.seer.cancer.gov
3. Prostate Cancer Treatment - NCIcancer.gov
4. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spreadpubmed.ncbi.nlm.nih.gov
5. Enlarged Prostate (Benign Prostatic Hyperplasia) - NIDDKniddk.nih.gov
6. Prostatitis: Inflammation of the Prostate - NIDDKniddk.nih.gov
7. Prostate Tests - NIDDKniddk.nih.gov
8. Bladder Cancer Stages - NCIcancer.gov
9. Definition of stage IV prostate cancer - NCI Dictionary of Cancer Termscancer.gov
10. Prostate Anatomy and ICD-O-3 - SEER Trainingtraining.seer.cancer.gov
11. International Agency for Research on Cancer: GLOBOCAN 2022 Prostate Fact Sheetgco.iarc.who.int
12. Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Updatepmc.ncbi.nlm.nih.gov
13. Prostate Cancer — Cancer Stat Factsseer.cancer.gov
14. Prostate Cancer Prevention (PDQ®)cancer.gov
15. New IARC study highlights that the large variability in prostate cancer incidence in Europe is indicative of overdiagnosisiarc.who.int
16. An assessment of GLOBOCAN methods for deriving national estimates of cancer incidenceiarc.who.int
17. NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American mencancer.gov
18. Cancer Disparitiescancer.gov
19. Prostate Cancer Prevention (PDQ®)–Patient Version - NCIcancer.gov
20. Genetics of Prostate Cancer (PDQ®)–Health Professional Version - NCIcancer.gov
21. BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet - NCIcancer.gov
22. BRCA1 and BRCA2 (PDQ®) - NCIcancer.gov
23. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variantsnature.com
24. Genetic Testing Fact Sheet - NCIcancer.gov
25. Hormone Therapy for Prostate Cancercancer.gov
26. The molecular taxonomy of primary prostate cancerpmc.ncbi.nlm.nih.gov
27. Integrative clinical genomics of advanced prostate cancerpmc.ncbi.nlm.nih.gov
28. The Evolutionary History of Lethal Metastatic Prostate Cancerpmc.ncbi.nlm.nih.gov
29. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthpubmed.ncbi.nlm.nih.gov
30. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancerpubmed.ncbi.nlm.nih.gov
31. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancerpmc.ncbi.nlm.nih.gov
32. Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumorspmc.ncbi.nlm.nih.gov
33. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinomapmc.ncbi.nlm.nih.gov
34. Classification and Staging Systems - EAU Guidelines on Prostate Canceruroweb.org
35. The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostatepmc.ncbi.nlm.nih.gov
36. Tests to Diagnose and Stage Prostate Cancercancer.org
37. Metastatic Cancer: When Cancer Spreads - NCIcancer.gov
38. Signs and Symptoms of Prostate Cancercancer.org
39. Prostate Cancer Treatment (PDQ®)–Health Professional Versioncancer.gov
40. Treatments for Prostate Cancer Spread to Bonescancer.org
41. Definition of spinal cord compression - NCI Dictionary of Cancer Termscancer.gov
42. Bone Metastasescancer.org
43. Prostate Cancer Screening (PDQ®)–Patient Versioncancer.gov
44. Prostate-Specific Antigen (PSA) Testcancer.gov
45. Recommendation: Prostate Cancer: Screeninguspreventiveservicestaskforce.org
46. Prostate Cancer Screening (PDQ®)–Health Professional Versioncancer.gov
47. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trialcdas.cancer.gov
48. Final Recommendation Statement: Screening for Prostate Canceruspreventiveservicestaskforce.org
49. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)auanet.org
50. American Cancer Society Recommendations for Prostate Cancer Early Detectioncancer.org
51. Final Recommendation Statement: Prostate Cancer: Screeninguspreventiveservicestaskforce.org
52. Prostate Cancer Screening Testscancer.org
53. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screeningpmc.ncbi.nlm.nih.gov
54. PI-RADS® v2.1acr.org
55. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsypmc.ncbi.nlm.nih.gov
56. Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trialpmc.ncbi.nlm.nih.gov
57. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline 2022auanet.org
58. Diagnostic Evaluation - EAU Guidelines on Prostate Canceruroweb.org
59. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studypubmed.ncbi.nlm.nih.gov
60. Follow up - EAU Guidelines on Prostate Canceruroweb.org
61. Treatment - EAU Guidelines on Prostate Canceruroweb.org
62. Prostate Cancer - Summary of Changes 2023uroweb.org
63. EAU Guidelines on Prostate Cancer—Treatmenturoweb.org
64. A Phase III randomized controlled trial of Stereotactic Body Radiotherapy in localized prostate cancerpmc.ncbi.nlm.nih.gov
65. Brachytherapy to Treat Cancercancer.gov
66. Definition of abiraterone - NCI Drug Dictionarycancer.gov
67. Abiraterone Acetate - NCIcancer.gov
68. Hormone Therapy for Prostate Cancer - American Cancer Societycancer.org
69. Treatments Expanding for Metastatic Prostate Cancer - NCIcancer.gov
70. FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrencefda.gov
71. FDA approves darolutamide for metastatic castration-sensitive prostate cancerfda.gov
72. Intermittent versus continuous androgen deprivation in prostate cancerpubmed.ncbi.nlm.nih.gov
73. Definition of hormone-sensitive prostate cancer - NCI Dictionary of Cancer Termscancer.gov
74. Prostate Cancer Symptoms, Tests and Treatments - FDAfda.gov
75. Definition of docetaxel - NCI Drug Dictionarycancer.gov
76. Oncology (Cancer)/Hematologic Malignancies Approval Notifications - FDAfda.gov
77. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancerpmc.ncbi.nlm.nih.gov
78. FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancerfda.gov
79. FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancerfda.gov
80. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024)auanet.org
81. Following PSA Levels During and After Prostate Cancer Treatmentcancer.org
82. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directionsauau.auanet.org
83. Prostate Cancer — Cancer Stat Factsseer.cancer.gov
84. Sexual Health Issues in Men and Cancer Treatmentcancer.gov
85. Male Fertility and Cancercancer.gov
86. Radiation Proctitiscancer.gov
87. Urinary and Bladder Problems and Cancer Treatmentcancer.gov
88. Late Effects of Cancer Treatmentcancer.gov
89. Radiation Therapy Side Effectscancer.gov
90. Radiation Therapy for Prostate Cancer: EBRT, Brachytherapy, and Radiopharmaceuticalscancer.org
91. Palliative Care in Cancercancer.gov
92. Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)cancer.gov
93. Cancer Pain (PDQ®)–Patient Versioncancer.gov
94. Cancer Pain (PDQ®)–Health Professional Versioncancer.gov
95. Recommendations: Spinal metastases and metastatic spinal cord compressionnice.org.uk
96. Denosumab in men receiving androgen-deprivation therapy for prostate cancerpubmed.ncbi.nlm.nih.gov
97. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studypmc.ncbi.nlm.nih.gov
98. Recommendations: Prostate cancer—diagnosis and managementnice.org.uk
99. Finasteride for Prostate Cancer Preventioncancer.gov
100. Long-Term Effects of Finasteride on Prostate Cancer Mortalitymed-fom-urlgsci.sites.olt.ubc.ca
101. Effect of dutasteride on the risk of prostate cancerpubmed.ncbi.nlm.nih.gov
102. Selenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answerscancer.gov
103. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)cancer.gov
104. A prospective study of lifetime physical activity and prostate cancer incidence and mortalitypubmed.ncbi.nlm.nih.gov
105. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men.pubmed.ncbi.nlm.nih.gov
106. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERGstacks.cdc.gov
107. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.pubmed.ncbi.nlm.nih.gov
108. The Nobel Prize in Physiology or Medicine 1966nobelprize.org
109. Hormonal Therapy in Prostate Cancer: Historical Approachespmc.ncbi.nlm.nih.gov
110. Classification of prostatic carcinomaspubmed.ncbi.nlm.nih.gov
111. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical stagingpubmed.ncbi.nlm.nih.gov
112. Purification of a human prostate specific antigenpubmed.ncbi.nlm.nih.gov
113. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostatepubmed.ncbi.nlm.nih.gov
114. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3pmc.ncbi.nlm.nih.gov
115. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancerdiscovery.ucl.ac.uk
116. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trialpubmed.ncbi.nlm.nih.gov
117. NRG-GU009 (“PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiationnrgoncology.org
118. Tumor clone dynamics in lethal prostate cancerpubmed.ncbi.nlm.nih.gov
119. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancerpmc.ncbi.nlm.nih.gov
120. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interferencepubmed.ncbi.nlm.nih.gov
121. Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvementpubmed.ncbi.nlm.nih.gov
122. Is a Genomic Test Better at Finding Aggressive Prostate Cancer?cancer.gov
123. PSMA PET-CT Accurately Detects Prostate Cancer Spreadcancer.gov
124. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteriapubmed.ncbi.nlm.nih.gov